The receptors for the glucagon-like peptide-1 (GLP-1R), glucose-dependent insulinotropic polypeptide (GIPR), and glucagon (GCGR) are major pharmacological targets in metabolic diseases such as type 2 diabetes (T2D) and obesity (1). This evidence concerns the gene GIPR and metabolic disease.